TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
HeraMED Ltd. ( (AU:HMD) ) has provided an update.
HeraMED Limited has announced that its HeraBEAT fetal heart rate monitor has received an upgraded Class IIb regulatory classification from the TGA, making it the only remote home-use device of its kind approved for the Australian market. This new classification positions HeraBEAT uniquely in the market, opening significant commercial opportunities for HeraMED as it plans to expand its presence in Australia by targeting large health systems and private clinics.
More about HeraMED Ltd.
HeraMED Limited is an innovative medical data and technology company that is pioneering digital maternity care. The company offers a proprietary platform called HeraCARE, which integrates hardware and software to transform prenatal and postpartum experiences. HeraMED’s solutions, including the HeraBEAT fetal heart rate monitor, utilize cloud computing, artificial intelligence, and big data to enhance the doctor-patient relationship, improve maternal health care, and enable early detection and prevention of potential risks.
Average Trading Volume: 1,586,464
Technical Sentiment Signal: Buy
Current Market Cap: A$38.56M
See more data about HMD stock on TipRanks’ Stock Analysis page.